PMA device
OPRA Implant System
Integrum AB · Osseoanchored Prostheses For The Rehabilitation Of Transfemoral Amputees (PJY, Class III) · First FDA decision Dec 18, 2020, newest Mar 12, 2026Limb loss and prosthetics
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
9
Naming "OPRA"
MAUDE reports
247
Brand "OPRA", since 2015
PubMed studies
200
Mentioning "OPRA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OPRA Implant System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- OPRA Implant SystemPMA supplement
P190009-S010 · Decided Mar 12, 2026 · 167 days after receipt · Normal 180 Day Track No User Fee
Device type: Osseoanchored prostheses for the rehabilitation of transfemoral amputees (PJY) · Orthopedic Surgery
- OPRA Implant SystemPMA supplement
P190009-S009 · Decided Aug 14, 2025 · 21 days after receipt · Normal 180 Day Track No User Fee
Device type: Osseoanchored prostheses for the rehabilitation of transfemoral amputees (PJY) · Orthopedic Surgery
- OPRA Implant SystemPMA supplement
P190009-S007 · Decided Jan 15, 2025 · 89 days after receipt · Normal 180 Day Track No User Fee
Device type: Osseoanchored prostheses for the rehabilitation of transfemoral amputees (PJY) · Orthopedic Surgery
3 more FDA decisions with a free account
Older decisions: P190009
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Chiropractic ServicesLocal determinationIn effectL37254CGS Administrators, LLCUpdated Feb 20, 2026
- Chiropractic ServicesLocal determinationIn effectL37387Palmetto GBAUpdated Dec 13, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "OPRA", any status and sponsor, newest update first.
- Magnetic Bead Tracking System and eOPRA Implant System With Bionic Prosthesis for Transtibial AmputeesActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06391697 · 7 participants (planned) · Start May 1, 2024 · Primary completion Sep 2, 2026
Device: eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System · For: Amputation
Sites: Boston, Massachusetts; Cambridge, Massachusetts
- Transtibial OsseointegrationRecruiting
Walter Reed National Military Medical CenterFederal agency
NCT06636136 · 30 participants (planned) · Start May 20, 2025 · Primary completion Apr 30, 2028
Device: OPRA · For: Amputation; Traumatic, Leg, Lower
Sites: Bethesda, Maryland; Philadelphia, Pennsylvania
IntegrumNot on our public-company list
NCT06753110 · 70 participants (planned) · Start Feb 19, 2025 · Primary completion Dec 2025
Device: OPRA transhumeral · For: Amputation of Upper Limb
Sites: Melbourne, Australia; Vienna, Austria; Ghent, Belgium · 6 sites in all
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OPRA", and for the whole product code for context.
This brand
247 reports: 90 malfunction, 157 injury, 0 death
Whole product code PJY
291 reports: 124 malfunction, 166 injury, 1 death
Newest reports for this brand
MW6004074 · Received Oct 16, 2026 · Event dated Jan 1, 2026
Device type: Osseoanchored Prostheses For The Rehabilitation Of Transfemoral Amputees (PJY)
Device problem as coded: Connection Problem; Detachment of Device or Device Component; Loosening of Implant Not Related to Bone-Ingrowth
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
MW6004075 · Received Oct 16, 2026 · Event dated Jan 1, 2026
Device type: Osseoanchored Prostheses For The Rehabilitation Of Transfemoral Amputees (PJY)
Device problem as coded: Connection Problem; Detachment of Device or Device Component; Loosening of Implant Not Related to Bone-Ingrowth
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- OPRA Implant SystemInjury
3011386779-2026-00282 · Received Oct 2, 2026 · Event dated Sep 9, 2026
Device type: Osseoanchored Prostheses For The Rehabilitation Of Transfemoral Amputees (PJY)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Unspecified Infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "OPRA"[tiab]. The summary above synthesizes these.
- Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
Verheij FS, Omer DM, Williams H, et al. · J Clin Oncol · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.
Williams H, Fokas E, Diefenhardt M, et al. · Ann Oncol · 2025Clinical Trial, Phase II, Multicenter Study
- Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
Fokas E, Williams H, Diefenhardt M, et al. · Eur J Cancer · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Audisio A, Gallio C, Velenik V, et al. · JAMA Oncol · 2025Multicenter Study
- Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM, Omer DM, Lin S, et al. · JAMA Netw Open · 2024Randomized Controlled Trial, Multicenter Study
- Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?
Sütcüoğlu O, Rustamova Cennet N, Özet A, et al. · J Clin Oncol · 2023Letter, Comment
- MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Williams H, Omer DM, Thompson HM, et al. · Radiology · 2024Randomized Controlled Trial
- Work-related ill-health in radiographers.
Hulls PM, Money A, Agius RM, et al. · Occup Med (Lond) · 2018
- Osteocalcin and frailty among older women.
Paulin TK, Malmgren L, Bartosch P, et al. · Aging Clin Exp Res · 2025
- OPRA-RS: A Hearing-Aid Fitting Method Based on Automatic Speech Recognition and Random Search.
Gonçalves Braz L, Fontan L, Pinquier J, et al. · Front Neurosci · 2022
- Assessing the OPRA Trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal cancer.
Zambare W, Miranda J, Horvat N, et al. · Surg Oncol Insight · 2024
- Total neoadjuvant therapy: Fact, fantasy, or fallacy?
Nagarajan A · Surg Oncol · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.